Description

Ethosuximide (CAS 77-67-8) is a high-purity pharmaceutical and research-grade compound with the molecular formula C₇H₁₁NO₂ and IUPAC name 3-ethyl-3-methylpyrrolidine-2,5-dione. This white to off-white crystalline powder is widely recognized for its role as an anticonvulsant, specifically targeting absence seizures. Ethosuximide is synthesized under stringent quality controls to ensure >98% purity, verified by HPLC and NMR analysis. It is soluble in organic solvents such as ethanol and DMSO but exhibits limited solubility in water. Suitable for laboratory research, pharmacological studies, and reference standards, this product is supplied in sealed, light-resistant containers to maintain stability. Store at 2-8°C in a dry environment to prolong shelf life.

Properties

• CAS Number: 77-67-8
• Complexity: 188
• IUPAC Name: 3-ethyl-3-methyl-pyrrolidine-2,5-dione
• InChI: InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
• InChI Key: HAPOVYFOVVWLRS-UHFFFAOYSA-N
• Exact Mass: 141.078978594
• Molecular Formula: C7H11NO2
• Molecular Weight: 141.17
• SMILES: CCC1(CC(=O)NC1=O)C
• Topological: 46.2
• Monoisotopic Mass: 141.078978594
• Physical Description: Solid
• Color/Form: Crystals from acetone and ether
• Odor: CHARACTERISTIC ODOR
• Stability/Shelf Life: Commercially available capsules have an expiration date of 5 years and the oral solution has an expiration date of 4 years following the date of manufacture.
• Synonyms: ethosuximide, 77-67-8, Etosuximida, Ethosuxide, Pyknolepsinum, 2-Ethyl-2-methylsuccinimide, Ethosuccimide, Ethosuccinimide, Atysmal, Suxilep, Suxinutin, 3-Ethyl-3-methylpyrrolidine-2,5-dione, Etosuximid, Mesentol, Pentinimid, Peptinimid, Petinimid, Succimal, Succimitin, Thetamid, Zaraondan, Zarondan, Zartalin, Asamid, Capitus, Etomal, Pemalin, Ronton, Simatin, Suximal, Zarodan, Pemal, Suxin, Aethosuximide, Piknolepsin, Thilopemal, Epileo Petit MAL, Zarondan-Saft, Ethosuximidum, 3-Ethyl-3-methyl-2,5-pyrrolidinedione, 3-Methyl-3-ethylsuccinimide, Aethosuccimidum, Etosuximide, 2-Methyl-2-ethylsuccinimide, CI-366, 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, 3-Ethyl-3-methylsuccinimide, Etosuccimide, PM-671, Succinimide, 2-ethyl-2-methyl-, CN-10,395, PM 671, alpha-Ethyl-alpha-methylsuccinimide, alpha-Methyl-alpha-ethylsuccinimide, 3-Methyl-3-ethylpyrrolidine-2,5-dione, N-Ethyl methylsuccinimide, gamma-Methyl-gamma-ethyl-succinimide, C.I. 366, H 940, H-490, Ethosuximidum [INN-Latin], Etosuximida [INN-Spanish], CN-10395, (+-)-2-Ethyl-2-methylsuccinimide, NSC-64013, HSDB 1119, UNII-5SEH9X1D1D, gamma-ethyl-gamma-methyl-succinimide, EINECS 201-048-7, 5SEH9X1D1D, CI 366, NSC 64013, BRN 0117054, CHEBI:4887, DTXSID7023019, NSC64013, DTXCID203019, Ethosuccimid, 5-21-09-00595 (Beilstein Handbook Reference), Ethylmethylsuccimide, Ethosuximide [USAN:USP:INN:BAN:JAN], Ethosuximidum (INN-Latin), Etosuximida (INN-Spanish), ETHOSUXIMIDE (MART.), ETHOSUXIMIDE [MART.], ETHOSUXIMIDE (USP-RS), ETHOSUXIMIDE [USP-RS], ETHOSUXIMIDE (EP MONOGRAPH), ETHOSUXIMIDE [EP MONOGRAPH], ETHOSUXIMIDE (USP MONOGRAPH), ETHOSUXIMIDE [USP MONOGRAPH], Ethosuximide (USAN:USP:INN:BAN:JAN), Ethosuximid, N03AD01, (2RS)-2-Ethyl-2-methylsuccinimide, 201-048-7, Zarontin, Petnidan, Emeside, Ethymal, Simatin(E), Cl 366, MFCD00072123, 3-Ethyl-3-methylpyrroline-2,5-dione, CHEMBL696, .alpha.-Ethyl-.alpha.-methylsuccinimide, 3-ethyl-3-methyl-pyrrolidine-2,5-dione, (+/-)-2-ethyl-2-methylsuccinimide, .gamma.-Methyl-.gamma.-ethylsuccinimide, Etosuccimide [DCIT], Aethosuximide [German], Pyknole.psi.num, Piknole.psi.n, Zarontin (TN), SR-01000075863, CAS-77-67-8, NCGC00016320-01, Prestwick_611, Spectrum_001385, Ethosuximide (Standard), Prestwick0_000165, Prestwick1_000165, Prestwick2_000165, Prestwick3_000165, Spectrum2_001483, Spectrum3_000944, Spectrum4_001051, Spectrum5_001073, ETHOSUXIMIDE [MI], E0746, (.+/-.)-Ethosuximide, ETHOSUXIMIDE [INN], ETHOSUXIMIDE [JAN], 2, 3-ethyl-3-methyl-, E 7138, ETHOSUXIMIDE [HSDB], ETHOSUXIMIDE [USAN], ETHOSUXIMIDE [VANDF], NCIOpen2_000014, Lopac0_000532, SCHEMBL34212, BSPBio_000029, KBioGR_001342, KBioSS_001865, DivK1c_000218, ETHOSUXIMIDE [WHO-DD], ETHOSUXIMIDE [WHO-IP], SPECTRUM1502196, 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, (+-)-, SPBio_001465, SPBio_001950, BPBio1_000033, GTPL7182, WLN: T5VMVTJ D2 D1, SCHEMBL20541518, Ethosuximide (JP18/USP/INN), Ethosuximide, analytical standard, HMS500K20, HY-B1378R, KBio1_000218, KBio2_001865, KBio2_004433, KBio2_007001, KBio3_002008, NINDS_000218, ETHOSUXIMIDE [ORANGE BOOK], GLXC-06110, HMS1568B11, HMS1921L14, HMS2092D20, HMS2095B11, HMS3261L05, HMS3712B11, HMS3885D12, HMS5083G04, Pharmakon1600-01502196, HY-B1378, MSK10713, Ethosuximide 1.0 mg/ml in Methanol, Tox21_110370, Tox21_500532, BDBM50240424, CCG-39217, ETHOSUXIMIDUM [WHO-IP LATIN], NSC758192, s4626, 3-ethyl-3-methylazolidine-2,5-dione, AKOS005261742, Tox21_110370_1, CS-7976, DB00593, FE22867, LP00532, NSC-758192, SDCCGSBI-0050515.P004, .alpha.-Methyl-.alpha.-ethylsuccinimide, IDI1_000218, NCGC00015418-02, NCGC00015418-03, NCGC00015418-04, NCGC00015418-05, NCGC00015418-06, NCGC00015418-08, NCGC00015418-09, NCGC00015418-15, NCGC00093923-01, NCGC00093923-02, NCGC00093923-03, NCGC00093923-04, NCGC00261217-01, 3-Ethyl-3-methyl-2, 5-pyrrolidinedione, AS-16859, DA-63296, SBI-0050515.P003, 2, 5-Pyrrolidinedione, 3-ethyl-3-methyl-, AB00052288, EU-0100532, NS00010826, ST51037248, C07505, D00539, D70258, EN300-123801, AB00052288_04, zarontin3-Ethyl-3-methyl-pyrrolidine-2,5-dione, Q421567, SR-01000075863-1, SR-01000075863-3, SR-01000075863-5, 3-Ethyl-3-methyl-pyrrolidine-2,5-dione(Ethosuximide), BRD-A99633051-001-04-7, BRD-A99633051-001-05-4, BRD-A99633051-001-07-0, BRD-A99633051-001-08-8, 3-Ethyl-3-methyl-pyrrolidine-2,5-dione (ethosuximide), Z384975088, 3-ethyl-5-hydroxy-3-methyl-3,4-dihydro-2H-pyrrol-2-one, 4-ethyl-5-hydroxy-4-methyl-3,4-dihydro-2H-pyrrol-2-one, 2,5-PYRROLIDINEDIONE, 3-ETHYL-3-METHYL-, (+/-)-, Ethosuximide, European Pharmacopoeia (EP) Reference Standard, Ethosuximide, United States Pharmacopeia (USP) Reference Standard

Application

Ethosuximide is primarily used as an anticonvulsant medication for the treatment of absence (petit mal) seizures. It functions by inhibiting T-type calcium channels in the thalamus, thereby stabilizing neuronal activity. Researchers also employ ethosuximide in neuropharmacology studies to investigate seizure mechanisms and antiepileptic drug efficacy. Its well-characterized pharmacokinetics make it a valuable tool for in vitro and in vivo experimental models.

Safety and Hazards

GHS Hazard Statements

• H302 (95.7%): Harmful if swallowed [Warning Acute toxicity, oral]

Precautionary Statements

• P264, P270, P301+P317, P330, and P501

Hazard Classes and Categories

• Acute Tox. 4 (95.7%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.